DUGiDocsAvaluació de la utilitat del monitoratge farmacocinètic dels fàrmacs anti-TNF en pacients amb malaltia inflamatòria intestinal en dos hospitals amb diferent grau d’especialització
Text Complet
Compartir
The tumor necrosis factor (TNF) acts as a potent inducer of inflammation in autoimmune diseases like Crohn disease and ulcerative colitis. Current available treatments are based on TNF inhibition such as infliximab and adalimumab. These drugs are very effective in inducing and maintaining remission. However, there is a high proportion of patients that lose their initial response over time. Recently, some studies have used therapeutic anti-TNF monitoring tools in order to adjust treatments according to each patient.
We have conducted a prospective multicenter study to determine the usefulness of therapeutic anti-TNF monitoring in patients with Crohn disease or ulcerative colitis in two centers with a different degree of specialization.
The results have allowed us to assess the clinical and economic impact of therapeutic anti-TNF monitoring in each center. Moreover, they have let us to determine which variables might influence the pharmacokinetics of these anti-TNF drugs
L'accés als continguts d'aquesta tesi queda condicionat a l'acceptació de les condicions d'ús establertes per la següent llicència Creative Commons: http://creativecommons.org/licenses/by-nc-nd/4.0/
Localització